Estradiol and womb lining thickness after weight-loss surgery in postmenopausal women with obesity
Follows postmenopausal women with obesity after weight-loss surgery or non-surgical care.
Plain-language title generated from the registry record
Registry title: Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Key facts
- Where
- Cairo, EgyptSee the site
Where in Egypt
- Kasr Al Ainy Hospitals, Faculty of Medicine, Cairo UniversityCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kasr El Aini Hospital
- Trial code
- NCT07919054
- Record updated
- 5 November 2026
- Original description
Obesity changes how the body produces and processes estrogen. After menopause, higher estrogen exposure is linked to thickening of the lining of the womb (endometrium) and a higher risk of endometrial cancer. Bariatric (weight-loss) surgery produces large and lasting weight loss, but how it changes estradiol levels and the endometrium in postmenopausal women is not well described.Read full original descriptionShow less
Association Between Changes in Serum Estradiol Levels and Endometrial Thickness Following Bariatric Surgery in Postmenopausal Women With Obesity: a Prospective Longitudinal Study
Obesity changes how the body produces and processes estrogen. After menopause, higher estrogen exposure is linked to thickening of the lining of the womb (endometrium) and a higher risk of endometrial cancer. Bariatric (weight-loss) surgery produces large and lasting weight loss, but how it changes estradiol levels and the endometrium in postmenopausal women is not well described.
This prospective cohort study will follow 78 postmenopausal women with obesity who are eligible for bariatric surgery at Cairo University hospitals: 39 women who undergo bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass or one-anastomosis gastric bypass) as part of their routine care, and 39 matched women who choose non-surgical medical and lifestyle management. Serum estradiol and endometrial thickness (measured by transvaginal ultrasound) will be measured at baseline and again 6 and 12 months later. The study will compare these changes between the two groups and examine whether changes in estradiol are associated with changes in endometrial thickness and with weight loss.
Inclusion: Naturally postmenopausal women with more than 12 months of amenorrhea; Intact uterus; Obesity with full eligibility for bariatric surgery according to standard clinical guidelines (BMI 40 kg/m² or more, or BMI 35 kg/m² or more with obesity-related comorbidities); Surgical group: scheduled to undergo sleeve gastrectomy, Roux-en-Y gastric bypass or one-anastomosis gastric bypass; Non-surgical group: intending to follow non-surgical medical or lifestyle obesity management; Able and willing to undergo serial transvaginal ultrasound and blood sampling at baseline, 6 months and 12 months.
Exclusion: Previous hysterectomy; Current use of hormone replacement therapy, selective estrogen receptor modulators or other hormonal treatments expected to substantially alter endometrial thickness or estradiol levels; Failure to complete the 12-month follow-up period; Known endometrial carcinoma or atypical endometrial hyperplasia requiring immediate oncological treatment; Major uterine pathology preventing reliable measurement of endometrial thickness (e.g., large submucosal fibroids); Inability, medical contraindication or refusal to undergo serial transvaginal ultrasound.